Treatment of invasive mycoses in patients with neutropenia in the course of a systemic blood dyscrasia;Therapie invasiver mykosen bei neutropenischen patienten mit hamatologischen

Deutsche Medizinische Wochenschrift

Volumn 123, Issue 7, 1998, Pages 191-194

  Glasmacher, A ^a,b   Just Nubling G ^a,d   Molitor, E ^a,c  

^a GOETHE UNIVERSITY   (Germany)

^b Allgemeine Innere Medizin   (Germany)

^c UNIVERSITY HOSPITAL BONN   (Germany)

^d UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; DIPYRONE; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; PETHIDINE;

BLOOD DYSCRASIA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; DRUG FORMULATION; DRUG INDICATION; HUMAN; MYCOSIS; NEUTROPENIA; REVIEW;

EID: 0032512881     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1023862     Document Type: Review

References (37)

1. Anaissie, E. J., N. White, O. Uzun, C. Singer, G. P. Bodey, D. Matzke, N. Azarnia, G. Lopez-Berestein, U. Tx: Amphotericin B lipid complex (ABLC) versus amphotericin B (AMB) for treatment of hematogenous and invasive candidiasis. Proc. Intersc. Conf. Antimicrob. Agents Chemother. 35 (1995), LM49. (Abstract)
2. Arning, M., K. O. Kliche, A. H. Heer-Sonderhoff, A. Wehmeier: Infusion-related toxicity of three different amphotericin B formulations and its relation to cytokine plasma levels. Mycoses 38 (1995), 459-465.
3. Arning, M., R. E. Scharf: Prevention of amphotericin-B-induced nephrotoxicity by loading with sodium chloride. Klin. Wschr. 67 (1989), 1020-1028.
4. Bowden, R. A., M. Cuys, T. Gooley, R. D. Mamelok, J.-A. van Burik: Phase I study of amphotericin B colloidal dispersion for the treatment of invasive fungal infections after marrow transplant. J. Infect. Dis. 173 (1996), 1208-1215.
5. Caillot, D., O. Casasnovas, E. Solary, P. Chavanet, B. Bonnotte, G. Reny, F. Entezam, J. Lopez, A. Bonnin, H. Guy: Efficacy and tolerance of an amphotericin B lipid (Intralipid) emulsion in the treatment of candidaemia in neutropenic patients. J. Antimicrob. Chemother. 31 (1993), 161-169.
6. Caillot, D., O. Casasnovas, A. Bernard, J. F. Couaillier, C. Durand, B. Cuisenier, E. Solary, F. Piard, T. Petrella, A. Bonnin, G. Couillault, M. Dumas, H. Guy: Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J. Clin. Oncol. 15 (1997), 139-147.
7. Cornely, O. A., W. Hiddemann, H. Link et al.: Interventional antimicrobial therapy in febrile neutropenic patients. Paul-Ehrlich-Society for Chemotherapy (PEG) Study II. Ann. Hematol. 74 (Suppl. 1) (1997), A51. (Abstract).
8. Denning, D. W.: Treatment of invasive aspergillosis. J. Infect. 28 (Suppl. 1) (1994), 25-33.
9. Denning, D. W., J. Y. Lee, J. S. Hostetler, P. Pappas, C. A. Kauffman, D. H. Dewsnup, C. A. Galgiani, J. R. Graybill, A. M. Sugar, A. Catanzaro, H. A. Gallis, J. R. Perfect, B. Dockery, W. E. Dismukes, D. A. Stevens: NIAID mycoses study group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Amer. J. Med. 97 (1994), 135.
10. Denning, D. W.: Liposomal amphotericin B (AmBisome) therapy in invasive fungal infections. Arch. intern. Med. 155 (1995), 1093.
11. Denning, D. W.: Therapeutic outcome in invasive aspergillosis. Clin. Infect. Dis. 23 (1996), 608-615.
12. Denning, D. W., D. A. Stevens: Antifungal and surgical treatment of invasive aspergillosis: review of 2121 published cases. Rev. Infect. Dis. 12 (1990), 1147-1201.
13. Edwards, J. E. Jr.: International conference for the development of a consensus on the management and prevention of severe candidal infections. Clin. Infect. Dis. 25 (1997), 43-59.
14. Gallis, H. A., R. H. Drew, W. W. Picard: Amphotericin B. 30 years of experience. Rev. Infect. Dis. 12 (1990), 308-329.
15. Glasmacher, A., E. Molitor, J. Mezger, G. Marklein: Antifungal prophylaxis with itraconazole in neutropenic patients. Mycoses 39 (1996), 249-258.
16. Glasmacher, A., G. Marklein, G. Just-Nübling, C. Leutner, S. Ewig: Diagnostik systemischer Mykosen bei neutropenischen Patienten mit hämatologischen Systemerkrankungen. Dtsch. Med. Wschr. (1998), 157-160.
17. Goa, K. L., L. B. Barradell: Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. Drugs 50 (1995), 658-690.
18. Grant, S.M., S. P. Clissod: Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs 37 (1989), 310-344.
19. Groll, A., N. Giri, C. Gonzales, T. Sein, J. Bacher, C. Piscitelli, T. Walsh: Penetration of lipid formulation of amphotericin B into cerebrospinal fluid and brain tissue. Proc. Intersc. Conf. Antimicrob. Agents Chemother. 37 (1997), A90. (Abstract)
20. Heinemann, V., B. Kähny, U. Jehn, D. Mühlbayer, A. Debus, K. Wachholz, D. Bosse, H. J. Kolb, W. Wilmanns: Serum pharmacology of amphotericin B applied in lipid emulsions. Antimicrob. Agents Chemother. 41 (1997), 728-732.
21. Herbrecht, R.: Safety of amphotericin B colloidal dispersion (ABCD) in disseminated fungal infections. In Mackenzie, D. W. R. (Ed.): Amphotericin B colloidal dispersion (ABCD) in the treatment of disseminated fungal infections. (Royal Society of Medicine: London 1994), 49-56.
22. Hostetler, J. S., L. H. Hanson, D. A. Stevens: Effect of cyclodextrin on the pharmacology of antifungal oral azoles. Antimicrob. Agents Chemother. 36 (1992), 477-480.
23. Kreisel, W.: Therapie invasiver Aspergillosen mit Itraconazol. Eigene Erfahrungen und Literaturübersicht. Mycoses 37 (Suppl. 2) (1994), 42-51.
24. Leenders, A. C., S. de Marie: The use of lipid formulations of amphotericin B for systemic fungal infections. Leukemia 10 (1996), 1570-1575.
25. Mills, W.: Liposomal amphotericin B in the treatmen of fungal infections in neutropenic patients. Brit. J. Haematol. 86 (1994), 754.
26. Moreau, P., N. Milpied, N. Fayette, J. F. Ramee, J. L. Harousseau: Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with intralipid compared with conventional amphoteriticin B in neutropenic patients. J. Antimicrob. Chemother. 30 (1992), 535-541.
27. Perfect, J. R., M. H. Lindsay, R. H. Drew: Adverse drug reactions to systemic antifungals. Drug. Saf. 7 (1992), 323-363.
28. Prentice, H. G., I. M. Hann, R. Herbrecht et al.: A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Brit. J. Haematol. 98 (1997), 711-718.
29. Ranchère, J. Y., J. F. Latour, C. Fuhrmann, C. Lagallarde, F. Loreuil: Amphotericin B intralipid formulation. Stability and particle size. J. Antimicrob. Chemother. II 37 (1996), 1165-1169.
30. Schöffski, P., R. Wunder, D. Petersen, G. Schumann, B. Hertenstein, U. Schubert, A. Ganser, M. Freund: Amphotericin B in Intralipid. No evidence of improved toxicity profile. Proc. Intersc. Conf. Antimicrob. Agents Chemother. 36 (1996), LM36 (Abstract).
31. Silling-Engelhardt, G., W. Fegeler, N. Roos, C. Schwarz, M. Essink, W. Hiddemann, T. Büchner : Interventional treatment of unexplained fever (FUO) and documented infections in neutropenic patients with hematological malignancies. Fluconazole versus Ampho B/5-FC. Onkologie 17 (Suppl. 2) (1994), 142. (Abstract)
32. Tang, C. M., J. Cohen: Empiric antifungal therapy. Baillière's Clin. Infect. Dis. 2 (1995), 127-140.
33. Viscoli, C., C. Girmenia, A. Marinus, P. Martino, F. Meunier: A surveillance study of fungemia in cancer patients in Europe. Invasive Fungal Infections Cooperative Group (IFIG) of the EORTC. Proceedings of Trends in Fungal Infection III, Brussels (1995), 8-9.
34. Viscoli, C., E. Castagnola, M. T. Van Lint, C. Moroni, A. Garaventa, M. R. Rossi, R. Fanci, F. Menichetti, D. Caselli, M. Giacchino, M. Congiu: Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients. Europ. J. Cancer 32A (1996), 814-820.
35. Viviani, M. A.: Flucytosine - what is the future? J. Antimicrob. Chemother. 35 (1995), 241-244.
36. White, M. H., E. J. Anaissie, S. Kusne, J. R. Wingard, J. Hiemenz, A. Cantor, M. J. Gurwith, C. Du Mond, R. D. Mamelok, R. A. Bowden: Amphotericin B colloideal dispersion vs. amphotericin B as therapy for invasive aspergillosis. Clin. Infect. Dis. 24 (1997), 635-642.
37. Wingard, J. R.: Efficacy of amphotericin B lipid complex injection (ABLC) in bone marrow transplant recipients with life-threatening systemic mycoses. Bone Marrow Transplant. 19 (1997), 343.